# PAH-former: Transfer learning for efficient discovery of pulmonary arterial hypertension-associated genes

## TL;DR

This study introduces PAH-former, a deep learning model that identifies genes linked to pulmonary arterial hypertension using limited patient data and validates them experimentally.

## Contribution

A novel transfer learning approach called PAH-former for efficient discovery of PAH-associated genes from scarce data.

## Key findings

- PAH-former identified 134 candidate genes, including known and novel ones, predicted to influence PAH.
- RNA interference validation showed that knockdown of top candidates increased SOX18 expression.
- The model offers a broadly applicable strategy for gene discovery in rare diseases.

## Abstract

Pulmonary arterial hypertension (PAH) is a severe disease with limited effective therapies, making the discovery of new therapeutic targets crucial. While single-cell RNA sequencing (sc-RNA seq) offers a powerful tool for this purpose, its application is hampered by the scarcity of patient samples. This study addresses the problem of how to efficiently identify novel, functionally relevant disease-associated genes from limited publicly available data.

We employed transfer learning by fine-tuning Geneformer, a deep learning model, with public sc-RNA seq data from patients with PAH to create a specialized model called PAH-former. This model was used to perform in silico perturbation analysis to identify and rank candidate genes predicted to influence the disease state. For validation, we performed RNA interference-mediated knockdown of top novel candidate genes in human pulmonary artery endothelial cells and measured the expression of SRY-Box Transcription Factor 18 (SOX18), a signature gene of pulmonary arterial hypertension.

In silico perturbation analysis identified 134 candidate genes whose deletion was predicted to shift cells towards a disease phenotype. These included known disease-related genes as well as many novel ones. Subsequent in vitro validation demonstrated that knockdown of the candidate genes resulted in a significant increase in the expression of SOX18.

Our novel platform, PAH-former, provides a powerful and broadly applicable strategy for disease-related gene discovery. This approach enables the identification and validation of new candidate genes from limited data, promising to advance cell-specific mechanistic insights and accelerate therapeutic development for rare diseases like PAH. (248/300 words).